1Guth U,Arndt V,Stadlmann S,et al. Epidemiology in ovariancarcinoma:lessons from autopsy[J]. Gynecol Oncol,2015,138(2):417.
2Merabishvili VM,Bogdanova EM,Urmancheeva AF,etal. Age-related features of morbidity,mortality and morphologicalverification of ovarian carcinoma[J]. VoprOnkol,2010,56(2):144.
4Desmeules P,Trudel D,Turcotte S,et al. Prognostic significanceof TIMP-2,MMP-2,and MMP-9 on high-gradeserous ovarian carcinoma using digital image analysis[J]. Hum Pathol,2015,46(5):739.
5Ranjbar R,Nejatollahi F,Nedaei AA,et al. Expressionof vascular endothelial growth factor(VEGF)and epidermalgrowth factor receptor(EGFR)in patients with serousovarian carcinoma and their clinical significance[J].Iran J Cancer Prev,2015,8(4):e3 428.
6Suzuki M,Iwasaki M,Sugio A,et al. BAG3(BCL2-associatedathanogene 3)interacts with MMP-2 to positivelyregulate invasion by ovarian carcinoma cells[J]. CancerLett,2011,303(1):65.
7Ledermann JA,Raja FA,Fotopoulou C,et al. Newly diagnosedand relapsed epithelial ovarian carcinoma:ESMOClinical Practice Guidelines for diagnosis,treatmentand follow-up[J]. Ann Oncol,2013,24 :i24.
8Poon RT,Lau CP,Ho JW,et al. Tissue factor expressioncorrelates with tumor angiogenesis and invasiveness in humanhepatocellular carcinoma[J]. Clin Cancer Res,2003,9(14):5 339.
9Yabushita H,Shimazu M,Noguchi M,et al. Vascular endothelialgrowth factor activating matrix metalloproteinasein ascitic fluid during peritoneal dissemination of ovariancancer[J]. Oncol Rep,2003,10(1):89.
10Fishman DA,Liu Y,Ellerbroek SM,et al. Lysophosphatidicacid promotes matrix metalloproteinase(MMP)activationand MMP-dependent invasion in ovarian cancercells[J]. Cancer Res,2001,61(7):3 194.
